The Technical Analyst
Aptinyx Inc [APTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aptinyx Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.17% $0.0960
America/New_York / 29 des 2023 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6.50 mill |
| EPS: | -0.980 |
| P/E: | -0.0980 |
| Earnings Date: | Mar 27, 2024 |
| SharesOutstanding: | 67.72 mill |
| Avg Daily Volume: | 0.133 mill |
| RATING 2023-12-29 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0980 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.0980 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0920 - 0.100 ( +/- 4.17%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-01-03 | Khanna Ashish | Buy | 375 000 | Stock Option (Right to Buy) |
| 2023-01-03 | Riedel Norbert G | Buy | 420 000 | Stock Option (Right to Buy) |
| 2023-01-03 | Kidd Andrew | Buy | 700 000 | Stock Option (Right to Buy) |
| 2022-05-26 | Koppel Adam | Buy | 40 000 | Stock Option (Right to Buy) |
| 2022-05-26 | Koppel Adam | Buy | 40 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 97 transactions |
| Buy: 16 590 862 | Sell: 1 518 818 |
Forecast:
01:40 - $0.0690
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0960 (3.17% ) |
| Volume | 0.231 mill |
| Avg. Vol. | 0.133 mill |
| % of Avg. Vol | 173.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
APTX
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Last 10 Buy Signals
Latest Press Releases
2023-03-30 16:05:00 - Press Release
Aptinyx Reports On Fourth Quarter And Full Year 2022 Results And Highlights And Review Of Strategic Alternatives
Evanston, ill.--(business wire)--aptinyx inc. (nasdaq: aptx) today reported recent business updates and financial results for the fourth quarter and full year 2022. recent business updates in march, aptinyx completed an analysis of the data from the first 100 patients enrolled in its phase 2b clinical study of nyx-783 50 mg in patients with post-traumatic stress disorder (ptsd). the study was halted in february prior to its completion in support of the company's preservation of capital.
2023-02-27 16:03:00 - Press Release
Aptinyx Reports Results From Phase 2 Study Of Nyx-458 In Cognitive Impairment Associated With Parkinson's Disease And Dementia With Lewy Bodies And Provides Pipeline And Corporate Update
Evanston, ill.--(business wire)--aptinyx inc. (nasdaq: aptx), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a phase 2 clinical study evaluating the effects of nyx-458 in patients with cognitive impairment associated with parkinson's disease and dementia with lewy bodies.
2023-01-31 07:47:00 - Press Release
Aptinyx To Present At The Svb Securities Global Biopharma Conference
Evanston, ill.--( business wire )--aptinyx inc. (nasdaq: aptx), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that andy kidd, m.d., president & chief executive officer, will participate in a virtual fireside chat at the svb securities global biopharma conference on wednesday, february 15, 2023 at 10:00 a.m. et.
2022-11-10 07:45:00 - Press Release
Preclinical Data From Aptinyx's Nmda Receptor Modulators To Be Presented At The 52nd Annual Meeting Of The Society For Neuroscience
Evanston, ill.
2022-11-08 16:05:00 - Press Release
Aptinyx Reports Third Quarter 2022 Financial Results And Recent Highlights
Evanston, ill.
Latest News
2023-03-30 11:23:26 - Zacks Investment Research
Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Aptinyx Inc. (APTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2023-03-21 13:00:22 - Zacks Investment Research
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
2023-02-28 08:36:53 - InvestorPlace
Why Is Aptinyx (APTX) Stock Down 64% Today?
Aptinyx (NASDAQ: APTX ) stock is taking a beating on Tuesday after the company revealed results from a Phase 2 clinical trial. The bad news here is that this clinical trial failed to meet its primary endpoint.
2023-01-31 07:47:00 - Business Wire
Aptinyx to Present at the SVB Securities Global Biopharma Conference
EVANSTON, Ill.--( BUSINESS WIRE )--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.
2022-11-08 21:46:05 - Seeking Alpha
Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript
Aptinyx Inc. (NASDAQ:APTX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & IR Andy Kidd - President and CEO Ashish Khanna - CFO and CBO Kathryn King - SVP, Clinical and CMC Operations Conference Call Participants Charles Duncan - Cantor Fitzgerald Myles Minter - William Blair Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon and welcome to the Aptinyx Third Quarter 2022 Financial Results Conference Call.
2022-10-18 07:45:00 - Business Wire
Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
2022-08-12 12:48:14 - Zacks Investment Research
Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal
Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline
2022-08-07 07:13:05 - Seeking Alpha
Aptinyx Inc. (APTX) CEO Andy Kidd on Q2 2022 Results - Earnings Call Transcript
Aptinyx Inc. (NASDAQ:APTX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & Investor Relations Andy Kidd - President & Chief Executive Officer Ashish Khanna - Chief Financial Officer & Chief Business Officer Kathryn King - Senior Vice President, Clinical & CMC Operations Conference Call Participants Ritu Baral - Cowen Evan Hua - BMO Capital Markets Myles Minter - William Blair Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon and welcome to the Aptinyx Second Quarter 2022 Financial Results Conference Call.
2022-07-15 07:47:00 - Business Wire
Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial (888) 660-6390 (domestic) or (929) 203-1902
2022-05-18 07:37:00 - Business Wire
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022. A webcast recording of the presentat